CNS drug developers have to focus on physical safety and efficacy first, especially when developing products for rare disorders or diagnoses that are often unresponsive to other therapies. Although these products rarely have notable CNS mediated side effects, they fall under the FDA's requirement for an abuse potential assessment because they cross the blood-brain barrier.
Interest in the medical use of cannabis and cannabinoids continues to grow as patients and caregivers consider this option for treatment of unmet medical needs. Ever growing efforts to legalize cannabinoids in the US and Canada are creating an increased need to evaluate safe and effective use.
According to the new market research report launched by Inkwood Research, The Global Antithrombotic Drugs market was valued at nearly $24900 million in 2017 and is anticipated to reach $45100 million by 2026, growing at an estimated CAGR of 6.83%, during the forecast period 2018-2026.
At the heart of key challenges facing biologics laboratories today lies the volume and complexity of data created throughout the scientific process
FIRALIS S.A. announces the launch of the Biopred panel, an innovative RUO product that profiles thousands of mRNAs associated with inflammatory autoimmune disorders via a pioneering targeted mRNA profiling technology without RNA extraction.
New website provides practical solutions to challenges of medication adherence
Nobilis Therapeutics, today announced addition of Dr. Paula Schnurr, Dr. Barbara Rothbaum and Dr. Israel Liberzon to its Scientific Advisory Board.
Second of 2-part Series to Examine Spider and Dosing Plots
Featured as cover story in May 2018 issue